TY - JOUR
T1 - A five-year clinical evaluation of NORPLANTR contraceptive subdermal implants in Bangladeshi acceptors
AU - Akhter, Halida
AU - Dunson, Thomas R.
AU - Amatya, Ramesh N.
AU - Begum, K.
AU - Chowdhury, T.
AU - Dighe, Nootan
AU - Krueger, Sheri L.
AU - Rahman, S.
N1 - Funding Information:
The authors wish to express their gratitude to the BIRPERHT staff and the clinic staff at the three centers involved in the study. The authors also wish to thank Margaret Davis, Sara Jasinski and Deborah Moore of Family Health International (FHI) for their time and assistance in data management activities, to Karen Quick for table preparation, and to I-Cheng Chi, Carol Connell, Rosalie Dominik, Anita Flick, Jim McMahan. Tom Petrick, and Roberto Rivera of FHI for their insightful critique of the manuscript. Partial support for this work was provided by FHI with funds from the United States Agency for International Development (USAID). The views expressed in this artide, however, do not necessarily reflect those of the funding agency. FHI is an international nonprofit organization that conducts research and provides technical assistance in health, family planning, STDs, and AIDS. It is based in Research Triangle Park, North Carolina, USA.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1993/6
Y1 - 1993/6
N2 - A non-comparative study of the Norplant contraceptive subdermal implant system was conducted in Dhaka, Bangladesh. The study was designed to evaluate the contraceptive efficacy, safety and overall acceptability of Norplant implants. Six hundred women were enrolled in the clinical trial, which began in 1985 at three study sites. Follow-up visits were scheduled at 1, 3, and 6 months after Norplant implant insertion, and every six months thereafter until removal or at the end of five years. There were no post-insertion pregnancies during Norplant implant use in this study. After five years of Norplant implant use, there was no clinically significant change in body weight, systolic or diastolic blood pressure. Less than 3% of the women ever reported having any significant medical problems such as migraine, respiratory or cardiac problems during the study. The gross cumulative continuation rate was 41.2 per 100 women at the end of five years. The two most frequently reported reasons for discontinuation during the study were menstrual problems and desired pregnancy. Of the women who completed the five-year user satisfaction questionnaire, the majority of the women (86.3%) planned to continue using contraception after study completion. Of these women, approximately one-third said they planned to use another Norplant set. The findings presented suggest that the Norplant system is a highly effective, safe and acceptable method among Bangladeshi women.
AB - A non-comparative study of the Norplant contraceptive subdermal implant system was conducted in Dhaka, Bangladesh. The study was designed to evaluate the contraceptive efficacy, safety and overall acceptability of Norplant implants. Six hundred women were enrolled in the clinical trial, which began in 1985 at three study sites. Follow-up visits were scheduled at 1, 3, and 6 months after Norplant implant insertion, and every six months thereafter until removal or at the end of five years. There were no post-insertion pregnancies during Norplant implant use in this study. After five years of Norplant implant use, there was no clinically significant change in body weight, systolic or diastolic blood pressure. Less than 3% of the women ever reported having any significant medical problems such as migraine, respiratory or cardiac problems during the study. The gross cumulative continuation rate was 41.2 per 100 women at the end of five years. The two most frequently reported reasons for discontinuation during the study were menstrual problems and desired pregnancy. Of the women who completed the five-year user satisfaction questionnaire, the majority of the women (86.3%) planned to continue using contraception after study completion. Of these women, approximately one-third said they planned to use another Norplant set. The findings presented suggest that the Norplant system is a highly effective, safe and acceptable method among Bangladeshi women.
UR - http://www.scopus.com/inward/record.url?scp=0027157349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027157349&partnerID=8YFLogxK
U2 - 10.1016/0010-7824(93)90024-2
DO - 10.1016/0010-7824(93)90024-2
M3 - Article
C2 - 8334891
AN - SCOPUS:0027157349
SN - 0010-7824
VL - 47
SP - 569
EP - 582
JO - Contraception
JF - Contraception
IS - 6
ER -